|
|
|
|
|
Legal status
Patent revoked (after opposition at EPO)
| (51) | INT.CL. | C07D 401/04 | (2006.01) |
| A61K 31/4439 | (2006.01) | ||
| A61K 31/4184 | (2006.01) | ||
| A61P 35/00 | (2006.01) |
| (11) | Number of the document | 3348553 |
| (13) | Kind of document | T |
| (96) | European patent application number | 18157435.1 |
| Date of filing the European patent application | 2013-06-04 | |
| (97) | Date of publication of the European application | 2018-07-18 |
| (45) | Date of publication and mention of the grant of the patent | 2020-07-08 |
| (46) | Date of publication of the claims translation | 2020-09-25 |
| (30) | Number | Date | Country code |
| 201261656888 P | 2012-06-07 | US |
| (72) |
DILHAS, Anna, CH
OUERFELLI, Ouathek, US
SMITH, Nicholas D., US
HERBERT, Mark R., US
|
| (73) |
Sloan-Kettering Institute for Cancer Research,
1275 York Avenue, New York, NY 10065,
US
Aragon Pharmaceuticals, Inc., 10990 Wilshire Blvd. Suite 300, Los Angeles, CA 90024, US |
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Kristalinės androgeno receptoriaus moduliatoriaus formos |
| CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR |
| Payment date | Validity (years) | Amount | |
| 2024-05-09 | 12 | 289.00 EUR |
| Patent revoked (after opposition at EPO) | ||
| Invalidation date | 2024-05-16 |